GEN Exclusives

More »

GEN News Highlights

More »
Sep 9, 2009

Germany Sanctions MediGene’s Topical Treatment for Genital Warts

  • The German regulatory authorities approved MediGene’s topical genital warts treatment, Veregen®. Approval follows July’s positive assessment by the German, Austrian, and Spanish national regulatory bodies.

    German market approval is the first for Veregen in Europe, and the country will act as the reference member state for the decentralized process through which marketing authorization applications can be submitted for other European countries. MediGene says that the Austrian and Spanish authorities are expected to issue formal clearance within the next few months.

    Veregen has been available in the U.S. since December 2007 and has been distributed by the company’s licensee, Nycomed, since early 2009. The company similarly plans to distribute Veregen in Europe via partners. “I am confident that we will be able to conclude a marketing partnership for Germany within the next few weeks,” says Frank Mathias, Ph.D., MediGene’s CEO. In June MediGene signed a deal with Spanish company Juste SAQF for distribution of Veregen in Spain and Portugal.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »